The increasing adoption of cell-based assays for drug discovery and the rising prevalence of chronic diseases are some of the key factors driving the growth of the market.
Increasing Demand for Cell-Based Research
Cell-based research has become an essential part of drug discovery and development. The demand for cell-based assays has been increasing due to the need for a more accurate and efficient way of testing drug candidates. Gentle cell dissociation reagents are crucial in the process of isolating cells from tissues, enabling researchers to obtain a homogenous cell population for experiments. As a result, the demand for gentle cell dissociation reagents has been increasing. Increasing demand for cell-based assays is expected to drive the growth of the gentle cell dissociation reagent market.Rising Prevalence of Chronic Diseases
The rising prevalence of chronic diseases, such as cancer, neurological disorders, and cardiovascular diseases, has been driving the demand for cell-based therapies. Gentle cell dissociation reagents are used in the isolation and expansion of stem cells, which are used in cell-based therapies. According to a report by Grand View Research, the increasing prevalence of chronic diseases is expected to drive the growth of the global stem cell therapy market, which in turn is expected to drive the growth of the gentle cell dissociation reagent market.Advancements in Biotechnology and Pharmaceutical Industries
The biotechnology and pharmaceutical industries have been witnessing significant advancements in recent years. The increasing investment in research and development activities has resulted in the development of innovative drugs and therapies. Gentle cell dissociation reagents are crucial in the process of drug discovery and development, and the increasing demand for innovative drugs is expected to drive the growth of the gentle cell dissociation reagent market. According to a report by Zion Market Research, the increasing investment in the biotechnology and pharmaceutical industries is expected to drive the growth of the global gentle cell dissociation reagent market.Limited Awareness and High Cost of Gentle Cell Dissociation Reagents
Despite the increasing demand for gentle cell dissociation reagents, the market is restrained by limited awareness and the high cost of these reagents. Many researchers and laboratories are not aware of the benefits of gentle cell dissociation reagents, and therefore, continue to use harsh methods of cell dissociation. Additionally, the cost of gentle cell dissociation reagents is higher compared to traditional methods, which limits their adoption. The high cost of these reagents can be attributed to the use of high-quality enzymes and other reagents in their formulation. Furthermore, the use of gentle cell dissociation reagents requires specific protocols and equipment, which may require additional investment. The limited awareness and high cost of gentle cell dissociation reagents are expected to hinder the growth of the market. The report also suggests that manufacturers need to increase awareness among researchers and laboratories about the benefits of gentle cell dissociation reagents and develop cost-effective reagents to address this restraint.Connective Tissue Segment Dominating the Revenue Share
Connective tissue held the largest revenue share in 2022, owing to the increasing use of gentle cell dissociation reagents in the isolation and culture of cells from various connective tissues. Connective tissue cells play a vital role in the development of various organs and tissues, making their isolation and culture essential in several biomedical research studies. On the other hand, the epithelial tissue segment is expected to grow at the highest CAGR during the forecast period of 2023 to 2031.Epithelial cells are the primary cells that line various organs and tissues, and their isolation and culture are crucial in several biomedical research studies. The increasing demand for epithelial cells for research purposes is expected to drive the growth of the gentle cell dissociation reagent market.
The Laboratory Segment Dominating the Revenue Share
The laboratory segment held the largest revenue share of the market in 2022, owing to the increasing use of gentle cell dissociation reagents in various laboratory procedures for the isolation and culture of cells. The rising demand for cell-based assays in drug discovery and development, cancer research, and other biomedical studies is expected to drive the growth of the market in this segment. The hospital segment is expected to grow at the highest CAGR during the forecast period. The increasing prevalence of chronic diseases such as cancer and the rising demand for personalized medicine is expected to drive the growth of the gentle cell dissociation reagent market in this segment. Hospitals and clinics are increasingly adopting gentle cell dissociation reagents for the isolation and culture of cells for diagnosis and treatment purposes.North America Leads the Revenue, while APAC to Lead the Market Growth
North America held the largest share of the market in 2022, owing to the presence of a large number of biotechnology and pharmaceutical companies, academic and research institutes, and hospitals in the region. The increasing adoption of cell-based assays in drug discovery and development, cancer research, and other biomedical studies is expected to drive the growth of the market in this region. Additionally, the increasing prevalence of chronic diseases, such as cancer and autoimmune disorders, is also expected to drive the growth of the market in this region. Asia Pacific is expected to grow at the highest CAGR during the forecast period of 2023 to 2031.The increasing focus on biomedical research and development, growing investments in healthcare infrastructure, and the rising prevalence of chronic diseases in the region are expected to drive the growth of the market in this region. The increasing adoption of personalized medicine and the growing demand for cell-based assays for drug discovery and development is also expected to drive the growth of the market in this region.
Competition to Intensify During the Forecast Period
The global gentle cell dissociation reagent market is highly competitive and is characterized by the presence of several major players. Some of the key players operating in the market include Thermo Fisher Scientific, Inc., Merck KGaA, STEMCELL Technologies, ATCC, MiltenyiBiotec GmbH, Biological Industries, PromoCell GmbH, Corning Incorporated, Lonza, HiMedia Laboratories and Other Notable Players. These companies are actively involved in strategic initiatives, such as mergers and acquisitions, collaborations, partnerships, and product launches, to strengthen their market position. For instance, in May 2021, Thermo Fisher Scientific, Inc. announced the launch of its new Gibco CTS Rotea Counterflow Centrifugation System, a next-generation cell therapy manufacturing platform. The platform includes gentle cell dissociation reagents that are optimized for the production of cell and gene therapies. The increasing focus on personalized medicine, the growing demand for cell-based assays in drug discovery and development, and the rising prevalence of chronic diseases are expected to drive the growth of the market during the forecast period.Historical & Forecast Period
This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2031.The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Gentle Cell Dissociation Reagent market are as follows:- Research and development budgets of manufacturers and government spending
- Revenues of key companies in the market segment
- Number of end users and consumption volume, price and value.
- Geographical revenues generate by countries considered in the report
- Micro and macro environment factors that are currently influencing the Gentle Cell Dissociation Reagent market and their expected impact during the forecast period.
Market Segmentation
Type
- Connective Tissue
- Epithelial Tissue
- Other
Application
- Laboratory
- Hospital
- Other
Key questions answered in this report
- What are the key micro and macro environmental factors that are impacting the growth of Gentle Cell Dissociation Reagent market?
- What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
- Estimated forecast and market projections up to 2031.
- Which segment accounts for the fastest CAGR during the forecast period?
- Which market segment holds a larger market share and why?
- Are low and middle-income economies investing in the Gentle Cell Dissociation Reagent market?
- Which is the largest regional market for Gentle Cell Dissociation Reagent market?
- What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
- Which are the key trends driving Gentle Cell Dissociation Reagent market growth?
- Who are the key competitors and what are their key strategies to enhance their market presence in the Gentle Cell Dissociation Reagent market worldwide?
This product will be delivered within 2 business days.
Table of Contents
Companies Mentioned
- Thermo Fisher Scientific Inc.
- Merck KGaA
- STEMCELL Technologies
- ATCC
- MiltenyiBiotec GmbH
- Biological Industries
- PromoCell GmbH
- Corning Incorporated
- Lonza
- HiMedia Laboratories